李氏大藥廠(00950)腫瘤科藥物獲中國藥監局批准臨床試驗 X
14/06/2018 23:04
<匯港通訊> 李氏大藥廠(00950)宣布,於今年5月25日,集團獲中國藥監局批准就 TG02(一種新型口服多激酶抑制劑)進行臨床試驗。

TG02 是一種以 CDK9 為主要抑制靶點的多激酶抑制劑。TG02 針對惡性血液腫瘤和神經膠質瘤進行過臨床前及臨床研究。初步結果顯示出抗膠質瘤效果及良好的血腦障壁穿透力。

(WH)



Infocast Limited and its information providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.